180 related articles for article (PubMed ID: 17337079)
1. Biochemical anti-opioid action of NPFF2 receptors in rat spinal cord.
Gouardères C; Zajac JM
Neurosci Res; 2007 May; 58(1):91-4. PubMed ID: 17337079
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
3. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
4. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
Kersanté F; Moulédous L; Zajac JM; Mollereau C
Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
[TBL] [Abstract][Full Text] [Related]
5. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
6. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
[TBL] [Abstract][Full Text] [Related]
8. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
9. Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.
Cichewicz DL; Cox ML; Welch SP; Selley DE; Sim-Selley LJ
Eur J Pharmacol; 2004 Nov; 504(1-2):33-8. PubMed ID: 15507218
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain.
Shaqura MA; Zöllner C; Mousa SA; Stein C; Schäfer M
J Pharmacol Exp Ther; 2004 Feb; 308(2):712-8. PubMed ID: 14593084
[TBL] [Abstract][Full Text] [Related]
11. Anti-analgesia of a selective NPFF2 agonist depends on opioid activity.
Roussin A; Serre F; Gouardères C; Mazarguil H; Roumy M; Mollereau C; Zajac JM
Biochem Biophys Res Commun; 2005 Oct; 336(1):197-203. PubMed ID: 16129413
[TBL] [Abstract][Full Text] [Related]
12. Mu-opioid receptors are involved in the tolerance to nicotine antinociception.
Galeote L; Kieffer BL; Maldonado R; Berrendero F
J Neurochem; 2006 Apr; 97(2):416-23. PubMed ID: 16539669
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
14. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain.
Talbot JN; Happe HK; Murrin LC
J Pharmacol Exp Ther; 2005 Aug; 314(2):596-602. PubMed ID: 15860573
[TBL] [Abstract][Full Text] [Related]
15. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.
Maher CE; Martin TJ; Childers SR
Life Sci; 2005 Jul; 77(10):1140-54. PubMed ID: 15890372
[TBL] [Abstract][Full Text] [Related]
17. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
18. Sustained inhibition of neurotransmitter release from nontransient receptor potential vanilloid type 1-expressing primary afferents by mu-opioid receptor activation-enkephalin in the spinal cord.
Zhou HY; Chen SR; Chen H; Pan HL
J Pharmacol Exp Ther; 2008 Nov; 327(2):375-82. PubMed ID: 18669865
[TBL] [Abstract][Full Text] [Related]
19. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of spinal mu-opioid receptor function to activate G-protein by chronic naloxone treatment.
Narita M; Mizoguchi H; Nagase H; Suzuki T; Tseng LF
Brain Res; 2001 Sep; 913(2):170-3. PubMed ID: 11549382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
